Product
Supplier
Encyclopedia
Inquiry
GHK-CU 89030-95-5  AHK-CU buy - large image1
GHK-CU 89030-95-5  AHK-CU buy - image1
GHK-CU 89030-95-5  AHK-CU buy - image2
GHK-CU 89030-95-5  AHK-CU buy - image3
GHK-CU 89030-95-5  AHK-CU buy - image4
GHK-CU 89030-95-5  AHK-CU buy - image5
GHK-CU 89030-95-5  AHK-CU buy - image6

GHK-CU 89030-95-5 AHK-CU

7469 Inquiries

Unit Price:

$44-45/UNIT FOB

Get Latest Price
CAS No.:

2381089-83-2

Grade:

Industrial Grade

Content:

99%

Port:

shanghai

Brand:

orient

Packaging:

1KG, 5KG, 25KG

Sample Available:

Yes

Price valid (until):

2027-07-14

Company Type:
Trader
Location:
China
Payment Terms:
100% TT in advance
Average Lead Time:
10 days
Qualification:
Main Products:

pharmaceutical intermediates,peptides,electronic chemicals

  • Product Details

  • Seller Information

  • Inquiry History

  • Description
    Product Name: Dermorphin
    Synonyms: DERMORPHIN ACETATE;L-Tyr-D-Ala-L-Phe-Gly-L-Tyr-L-Pro-L-Ser-NH2;Tyrosyl-alanyl-phenylalanyl-glycyl-tyrosyl-prolyl-serinamide;Dermorphin trifluoroacetate salt;Dermorphin Powder;(2S)-N-[(2S)-1-amino-3-hydroxy-1-oxopropan-2-yl]-1-[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]-3-phenylpropanoyl]amino]acetyl]amino]-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carboxamide;Dermorphin HAc;(2S)-1-[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]-3-phenyl-propanoyl]amino]acetyl]amino]-3-(4-hydroxyphenyl)propanoyl]-N-[(1S)-1-carbamoyl-2-hydro
    CAS: 77614-16-5
    MF: C40H50N8O10
    MW: 802.87
    EINECS: 202-853-6
    Product Categories: 77614-16-5
    Mol File: 77614-16-5.mol
    Shop Dermorphin 77614-16-5 API-Detailed Image 1

    Dermorphin Chemical Properties
    Melting point  157-159 °C
    Boiling point  1323.8±65.0 °C(Predicted)
    density  1.363±0.06 g/cm3(Predicted)
    storage temp.  -20°C
    solubility  Soluble in DMSO
    form  powder
    pka 9.83±0.15(Predicted)
    color  white to off-white
    Sequence H-Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH2
    InChIKey FHZPGIUBXYVUOY-VWGYHWLBSA-N
    SMILES C(N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N)(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](C)NC(=O)[C@@H](N)CC1C=CC(O)=CC=1)CC1C=CC=CC=1)CC1C=CC(O)=CC=1

    Safety Information
    WGK Germany  3
    MSDS Information


    Dermorphin Usage And Synthesis
    Structure Dermorphin does not contain the common N-terminal sequence for the traditional endogenous  peptides (Tyr–Gly–Gly–Phe), and its sequence is completely different from those of the endomorphins, which were identified as endogenous μ- peptides that also do not contain the common sequence. Interestingly, DM contains D-alanine (a D-isomer amino acid) in its sequence. The primary structure of dermorphin is YDAFGYPS-NH2.
    Description Dermorphin was first isolated from the skin of the skin of South American frogs of the genus Phyllomedusa.  It is a high potency natural opiate peptide that binds selectively to mu- receptors.
    Uses A mu- receptor agonist
    Definition ChEBI: Dermorphin is an oligopeptide.
    Side effects Like μ-opiate agonists, dermorphins produce antinociception and also catalepsy, respiratory depression, constipation, tolerance, and dependence, although at a lower degree than   does[1].
    in vitro Dermorphin, a peptide isolated from the skin of Phyllomedusa frogs and the peptide receptor (NOP) component by the endogenous agonist nociceptin/orphanin FQ (N/OFQ). In displacement binding studies at CHOhMu, Dermorphin and DeNo displac the binding of [3H]-DPN in a concentration dependent and saturable manner. Dermorphin displays an affinity of 7.17, while N/OFQ fails to displace [3H]-DPN at the Delta receptor. Dermorphin and DeNo stimulate the binding of GTPγ[35S] in a concentration dependent and saturable manner at the Mu receptor.
    References [1] Negri, L. P. Melchiorri and R. Lattanzi. “ and Bv8 Peptides.”Handbook of Biologically Active Peptides (Second Edition) 2013:376-383.

    Shop Dermorphin 77614-16-5 API-Detailed Image 2 Shop Tirzepatide API Material-Detailed Image 4


    Shop Tirzepatide API Material-Detailed Image 5

    Shop Tirzepatide API Material-Detailed Image 6

    Shop Tirzepatide API Material-Detailed Image 7


    Shop Tirzepatide API Material-Detailed Image 8

    Shop Tirzepatide API Material-Detailed Image 9

    Shop Tirzepatide API Material-Detailed Image 10


    Shop Tirzepatide API Material-Detailed Image 11

    Q1:Do you provide sample?

    A: Yes, we can provide free sample, you only need pay the shipping cost.

    Q2: What is the lead time?

    A: For stock goods, it usually take about 5-7 days by air, 15-30 days by sea,For customized products, the delivery time needs to be confirmed based on the actual situation.

    Q3: How can I buy? What is the payment method?

    A: You can contract us through Email or you can browse our website:orientchem.cc, we have bank transfer, 

    Q4:What if there are quality issues?

    A:We attach great importance to after-sales service of our products. If there are any quality issues, please contact us within 30 days of receiving the goods and we will handle returns and exchanges for you.

    ECHEMI Editorial Reference
    Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide inhibits human GCGR, GIPR and GLP-1R with EC50 values of 5.79, 0.0643 and 0.775 nM, respectively and mouse GCGR, GIPR, and GLP-1R with EC50 values of 2.32, 0.191 and 0.794 nM, respectively. It is an important tool for obesity research.Retatrutide potently activates the GLP-1R signaling pathway to stimulate glucose-dependent insulin secretion through activity at the GIP receptor (GIPR) or the GLP-1R.Retatrutide is a synthetic peptide with glucose-lowering effects. It is an antidiabetic agent against type 2 diabetes (T2D), stimulating insulin and suppressing glucagon secretion in a glucose-dependent manner.Retatrutide was also shown to delay gastric emptying, lower fasting and postprandial glucose concentration, decrease food intake and reduce body weight in patients with type 2 diabetes.
    Retatrutide (LY-3437943) was discovered by the American pharmaceutical company Eli Lilly and Company. It is a triple glucagon hormone receptor agonist (GLP-1, GIP, and GCGR receptors) for obesity. The 2024 Lasker~DeBakey Clinical Medical Research Award has been given to Joel Habener and Svetlana Mojsov for their discovery of a new hormone GLP-1(7-37) and to Lotte Knudsen for her role in developing sustained acting versions of this hormone as a treatment for obesity.

    Basic Info
    Product Name:

    Retatrutide

    Other Name:

    Retatrutide;GIPR/GLP-1R;LY3437943Retatrutide;Retalutide;Retatrutide (sodium salt);Retatrutide RT5;retatrutide 5mg;Retatratide

    CAS No.:

    2381089-83-2

    InChIKeys:

    MLOLQJNKXBNWFW-SAGGEDDASA-N

    Molecular Weight:

    0

    EC Number:

    200-001-8

    Color/Form:

    White lyophilized

    Categories:

    Inhibitor Drugs

    Characteristics
    Water Solubility:

    Soluble in water (5mg/ml).

    Storage Conditions:

    -20°C

    Critical Temperature & Pressure:

    -20°C

    Research
    Class:

    Triple agonist — GCGR, GIPR, GLP-1R

    Status:

    Investigational (Phase 3)

    Mechanism:

    Simultaneously activates glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Engineered from the native GIP backbone with amino acid substitutions to confer GCGR and GLP-1R activity.

    EC50 (Human GCGR):

    5.79 nM

    EC50 (Mouse GIPR):

    0.191 nM

    EC50 (Mouse GLP1R):

    0.794 nM

    EC50 (Mouse GCGR):

    2.32 nM

    EC50 (Human GLP1R):

    0.775 nM

    EC50 (Human GIPR):

    0.0643 nM

    Source:

    Jastreboff AM, et al. N Engl J Med. 2023;389(6):514-526.DOI

    Clinical Development:

    NCT04881760; NCT05882045; NCT06354660

    References
    ChEMBL:

    CHEMBL5095485

    DrugBank:

    DB18993

    KEGG DRUG:

    D12430

    PubChem:

    PubChem

    Disclaimer:

    Retatrutide is an investigational compound not yet approved by FDA or EMA. This listing is for industrial and laboratory research use only. Product information on ECHEMI is provided for sourcing and specification reference. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.

  • Seller Information
    Business Type:

    Trader

    Main Products:

    pharmaceutical intermediates,peptides,electronic chemicals

    Location:

    Room 102, 1st Floor, East Office Building, No. 45 Pengwan Road, Qianwan Bonded Port Area, Qingdao Zone, China (Shandong) Pilot Free Trade Zone

    Payment Terms:

    100% TT in advance

    Average lead Time:

    10 days

    Total Annual Revenue:

    $10 million-$25 million

    Total Employees:

    51-100

    Year of Establishment:

    2024

    A reliable supplier is like insurance.

    We are mainly specilized in supply of pharmaceutical intermediates, electronic chemicals,food additives, and other fine chemical products.
    Integrity is the foundation, quality is life. We would like to work together with you to build a greener and brighter future.

    Website: orientchem.cc
    Email: scarlett@orientchem.cc
    WhatsApp: +86 17753254221

  • Inquiry History
    7469 Inquiries
    Country Product Purchase Quantity Date Posted
    Switzerland

    Retatrutide

    1 KG Oct 26, 2026
    United States

    Retatrutide

    10 MG Oct 26, 2026
    Australia

    Retatrutide

    30 MG Oct 26, 2026
    United States

    Retatrutide

    30 MG Oct 26, 2026
    United States

    Tesa

    2 MG Oct 25, 2026
    Colombia

    Retatrutide

    15 MG Oct 25, 2026
    United States

    Retatrutide

    10 G Oct 25, 2026
    Canada

    Retatrutide

    1 KG Oct 25, 2026
    United Kingdom

    Retatrutide

    1 G Oct 25, 2026
    Netherlands

    Retatrutide

    10 MG Oct 25, 2026
    Australia

    Retatrutide

    10 MG Oct 25, 2026
    Netherlands

    Retatrutide

    20 MG Oct 25, 2026
    Germany

    Retatrutide

    1 KG Oct 25, 2026
    United Kingdom

    Retatrutide

    10 G Oct 25, 2026
    United States

    Retatrutide

    20 MG Oct 25, 2026
    Poland

    Retatrutide

    20 MG Oct 25, 2026
    United States

    Retatrutide

    10 MT Oct 25, 2026
    United States

    Retatrutide

    300 MG Oct 25, 2026
    Germany

    Retatrutide

    1 MT Oct 24, 2026
    Malta

    Retatrutide

    10 MT Oct 24, 2026
    Post an enquiry for this product

More from this Seller

pic ×

Scan the QR Code to Share

All products displayed on this website are only for non-medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.

According to relevant laws and regulations and the regulations of this website, units or individuals who purchase hazardous materials should obtain valid qualifications and qualification conditions.

The information shown above is provided by the enterprise itself, and the authenticity, accuracy and legitimacy of the content are the responsibility of the publishing company. ECHEMI does not bear any guarantee responsibility for this. Please be aware that risks in internet transactions objectively exist.

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.